The role of the immune system in the pathophysiology of osteoporosis

Immunological Reviews

Volumn 208, Issue , 2005, Pages 207-227

  Clowes, Jackie A ^a   Riggs, B Lawrence ^a   Khosla, Sundeep ^a  

^a ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ESTRADIOL; ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE; RECOMBINANT OSTEOCLAST DIFFERENTIATION FACTOR; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

AGING; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE METABOLISM; BONE REMODELING; CELIAC DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; ENTERITIS; ESTROGEN DEFICIENCY; FRACTURE; GRAFT REJECTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SENILE OSTEOPOROSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VITAMIN D DEFICIENCY;

AGING; ANIMALS; B-LYMPHOCYTES; CARRIER PROTEINS; CELL DIFFERENTIATION; CYTOKINES; ESTROGENS; GLYCOPROTEINS; HUMANS; IMMUNE SYSTEM; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; VITAMIN D;

EID: 28544439444     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00334.x     Document Type: Review

References (178)

1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
2. Eddy DM, et al. Osteoporosis: review of the evidence for prevention, diagnosis, treatment and cost-effectiveness analysis. Osteoporos Int 1998;(Suppl. 4):S1-S88.
3. London D, Barlow D, Cooper C, Kanis J, Whitehead M. Osteoporosis: Clinical Guidelines for Prevention and Treatment. London: Royal College of Physicians 1999:1-86.
4. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302.
5. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-184.
6. Clowes JA, Eastell R. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:213-232.
7. Chapuy MC, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
8. Grados F, et al. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 2003;88:5175-5179.
9. Ho KY, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-58.
10. Boonen S, et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999;14:2150-2158.
11. Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ III, Khosla S. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 2004;19:1075-1083.
12. French RA, et al. Age-associated loss of bone marrow hematopoietic cells is reversed by GH and accompanies thymic reconstitution. Endocrinology 2002;143:690-699.
13. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996;17:369-384.
14. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203-1204.
15. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-1051.
16. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-137.
17. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004;5:133-139.
18. Linton PJ, Haynes L, Klinman NR, Swain SL. Antigen-independent changes in naive CD4 T cells with aging. J Exp Med 1996;184:1891-1900.
19. Vallejo AN, Weyand CM, Goronzy JJ. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 2004;10:119-124.
20. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
21. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003;176:293-304.
22. Yamamoto I, Potts JT Jr, Segre GV. Circulating bovine lymphocytes contain receptors for parathyroid hormone. J Clin Invest 1983;71:404-407.
23. Prowedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221:1181-1183.
24. Funk JL, et al. Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes. Endocrinology 1995;136:3412-3421.
25. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-179.
26. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:6800-6805.
27. O'Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002;109:1091-1099.
28. Mathieu C, et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001;16:2057-2065.
29. Panda DK, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 2001;98:7498-7503.
30. Fujita T, Matsui T, Nakao Y, Watanabe S. T lymphocyte subsets in osteoporosis. Effect of 1-alpha hydroxyvitamin D3. Miner Electrolyte Metab 1984;10:375-378.
31. Grcevic D, Lee SK, Marusic A, Lorenzo JA. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 2000;165:4231-4238.
32. John V, Hock JM, Short LL, Glasebrook AL, Galvin RJ. A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology 1996;137:2457-2463.
33. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003;23:117-145.
34. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
35. Khosla S. Minireview: the OPG/RANKL/ RANK system. Endocrinology 2001;142:5050-5055.
36. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
37. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
38. Yasuda H, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
39. Kwon BS, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845-854.
40. Hofbauer LC, Dunstan CR, Speisberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998;250:776-781.
41. Vidal ON, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998;248:696-700.
42. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-4370.
43. Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001;142:2205-2212.
44. Murakami T, et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998;252:747-752.
45. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
46. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-259.
47. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003;89:180-190.
48. Hofbauer LC, Schoppet M, Schuller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 2004;60:214-219.
49. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
50. Morony S, et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1,25(OH)2D3. J Bone Miner Res 1999;14:1478-1485.
51. Morony S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005;146:3235-3243.
52. Bucay N, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
53. Yano K, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-527.
54. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637.
55. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-3165.
56. Khosla S, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394-399.
57. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-686.
58. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-4475.
59. Takai H, et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273:27091-27096.
60. Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
61. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-4427.
62. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
63. Burgess TL, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-538.
64. Lum L, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-13618.
65. Yamamoto M, et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998;139:4012-4015.
66. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003;90:267-277.
67. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
68. Bekker PJ, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in post-menopausal women. J Bone Miner Res 2004;19:1059-1066.
69. Anderson DM, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
70. Hsu H, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545.
71. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-649.
72. Baron R. Arming the osteoclast. Nat Med 2004;10:458-460.
73. Nakagawa N, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
74. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
75. Li J, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-1571.
76. Arai F, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999;190:1741-1754.
77. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem 2001;83:320-325.
78. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829-7834.
79. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002;87:1550-1554.
80. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230.
81. Takeda S, et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999;140:1005-1008.
82. Li YC, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997;94:9831-9835.
83. Yoshizawa T, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997;16:391-396.
84. Li YC, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-4396.
85. Amling M, et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999;140:4982-4987.
86. Takahashi N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988;123:2600-2602.
87. Panda DK, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004;279:16754-16766.
88. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998;23:75-81.
89. Ross FP. RANKing the importance of measles virus in Paget's disease. J Clin Invest 2000;105:555-558.
90. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005;328:709-720.
91. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study - hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2000;13:1545-1554.
92. Rogers A, Eastell R. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J Bone Miner Res 1998;13:1577-1586.
93. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132-1136.
94. Sakuma Y, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000;15:218-227.
95. Pacifia R, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991;88:5134-5138.
96. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-290.
97. Cenci S, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229-1237.
98. Roggia C, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-13965.
99. Cenci S, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003;100:10405-10410.
100. Gao Y, et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004;101:16618-16623.
101. Arron JR, Choi Y. Bone versus immune system. Nature 2000;408:535-536.
102. Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.
103. Jilka RL, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.
104. Poli V, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-1196.
105. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000;96:1873-1878.
106. Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002;110:1643-1650.
107. Sims NA, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 2005;20:1093-1102.
108. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-149.
109. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001;98:2443-2448.
110. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-759.
111. Oursler MJ, et al. Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 1991;129:3313-3320.
112. Bommireddy R, Doetschman T. TGF-beta, T-cell tolerance and anti-CD3 therapy. Trends Mol Med 2004;10:3-9.
113. Hong MH, Williams H, Jin CH, Pike JW. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine- phosphorylated proteins. J Bone Miner Res 2000;15:911-918.
114. Miyamoto T, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554.
115. Thirunavukkarasu K, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001;276:36241- 36250.
116. Ross FP. Interleukin 7 and estrogen-induced bone loss. Trends Endocrinol Metab 2003;14:147-149.
117. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-2568.
118. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
119. Kotake S, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44:1003-1012.
120. Teng YT, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:R59-R67.
121. Shinoda K, et al. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 2003;33:711-720.
122. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003;100:125-130.
123. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997;158:5507-5513.
124. Erben RG, Harti G, Graf H. Ovariectomy does not alter CD4+/CD8+ ratio in peripheral blood T-lymphocytes in the rat. Horm Metab Res 1998;30:50-54.
125. Sass DA, et al. The role of the T-lymphocyte in estrogen deficiency osteopenia. J Bone Miner Res 1997;12:479-486.
126. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002;2:46-53.
127. Hustmyer FG, et al. Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res 1993;8:51-59.
128. Abrahamsen B, Bendtzen K, Beck-Nielsen H. Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone 1997;20:251-258.
129. Imai Y, Tsunenari T, Fukase M, Fujita T. Quantitative bone histomorphometry and circulating T lymphocyte subsets in postmenopausal osteoporosis. J Bone Miner Res 1990;S5:393-399.
130. Rosen CJ, Usiskin K, Owens M, Barlascini CO, Belsky M, Adler RA. T lymphocyte surface antigen markers in osteoporosis. J Bone Miner Res 1990;5:851-855.
131. Koberda J, Bergmann L, Mitrou PS, Hoelzer D. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells. J Cancer Res Clin Oncol 1991;117:425-430.
132. Ho PC, Tang GW, Lawton JW. Lymphocyte subsets in patients with oestrogen deficiency. J Reprod Immunol 1991;20:85-91.
133. Giglio T, et al. Immune cell circulating subsets are affected by gonadal function. Life Sci 1994;54:1305-1312.
134. Manabe N, et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001;167:2625-2631.
135. Yun TJ, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001;166:1482-1491.
136. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 2000;15:541-549.
137. Miyaura C, et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 1997;94:9360-9365.
138. Teitelbaum SL. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 2004;101:16711-16712.
139. Koga T, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758-763.
140. Mocsai A, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004;101:6158-6163.
141. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003;3:445-453.
142. Amano S, Kawakami K, Iwahashi H, Kitano S, Hanazawa S. Functional role of endogenous CD14 in lipopolysaccharide-stimulated bone resorption. J Cell Physiol 1997;173:301-309.
143. Johnson GB, Riggs BL, Platt JL. A genetic basis for the 'Adonis' phenotype of low adiposity and strong bones. FASEB J 2004;18:1282-1284.
144. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088.
145. Kikuchi T, et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001;166:3574-3579.
146. Suda K, et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J Immunol 2004;172:2504-2510.
147. Itoh K, et al. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 2003;170:3688-3695.
148. Vegeto E, Ghisletti S, Meda C, Etteri S, Belcredito S, Maggi A. Regulation of the lipopolysaccharide signal transduction pathway by 17beta-estradiol in macrophage cells. J Steroid Biochem Mol Biol 2004;91:59-66.
149. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
150. Heath WR, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26.
151. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 2004;104:1404-1410.
152. Chomarat P, Dantin C, Bennett L, Banchereau J, Palucka AK. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003;171:2262-2269.
153. Trevejo JM, et al. TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci USA 2001;98:12162-12167.
154. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510-514.
155. Josien R, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191:495-502.
156. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c+ CD11b (intermediate) dendritic cells from bone marrow precursors. J Immunol 2004;172:1426-1436.
157. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ. Predictors of hip fractures in elderly men. J Bone Miner Res 1995;10:1900-1907.
158. Melton LJ, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-221.
159. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
160. Epstein S, Inzerillo AM, Caminis J, Zaidi M. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003;18:2083-2094.
161. Vasquez H, et al. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000;95:183-189.
162. Collin P, Kaukinen K, Valimaki M, Salmi J. Endocrinological disorders and celiac disease. Endocr Rev 2002;23:464-483.
163. Taranta A, et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. J Bone Miner Res 2004;19:1112-1121.
164. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
165. Ashcroft AJ, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003;19:849-861.
166. Moschen AR, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-487.
167. Li X, Gu W, Masinde G, et al. Genetic variation in bone-regenerative capacity among inbred strains of mice. Bone 2001;29:134-140.
168. Sheng MH, Lau KH, Beamer WG, Baylink DJ, Wergedal JE. In vivo and in vitro evidence that the high osteoblastic activity in C3H/ HeJ mice compared to C57BL/6J mice is intrinsic to bone cells. Bone 2004;35:711-719.
169. Judex S, Garman R, Squire M, Busa B, Donahue LR, Rubin C. Genetically linked site-specificity of disuse osteoporosis. J Bone Miner Res 2004;19:607-613.
170. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 2005;20:1085-1092.
171. Whyte MP, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347:175-184.
172. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002;17:26-29.
173. Paloneva J, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003;198:669-675.
174. Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 2003;198:645-651.
175. Kaifu T, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003;111:323-332.
176. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
177. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
178. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs HL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274.